International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8187204
Original Article
Correlation Between PEFR and Pulmonary Score in Assessing Mild to Moderate Exacerbation of Bronchial Asthma in Children Aged 6-13 Years Treated at Government Medical College Ernakulam
 ,
 ,
Published
July 15, 2023
Abstract

Introduction: Asthma is a chronic inflammatory disorder characterized by cough, wheeze and breathlessness which is partly reversible. PEFR monitoring is a simpler tool to measure airflow obstruction. Pulmonary score is a useful scoring system to assess the asthma severity. As not much studies are available regarding the use of Pulmonary Score in grading the asthma exacerbations, we conducted a study on the correlation of PEFR values and Pulmonary score among children with mild and moderate exacerbation of bronchial asthma.

Methods: A descriptive diagnostic test evaluation was conducted in 50 children with acute exacerbation of asthma aged 6-13 years attending the Paediatric emergency room, Government Medical College Ernakulam over a period of 1 year. Children were classified according to PEFR and Pulmonary Score as mild and moderate exacerbation. Treatment was started according to standard protocol of asthma management. PEFR and pulmonary scoring were done again 20 minutes after bronchodilator therapy and improvement in both were statistically calculated and compared.

Conclusion: In our study there was a significant negative correlation between pre-treatment and post- treatment PEFR & PS with a pre-treatment correlation coefficient of -0.657 (P value 0.0001) and post-treatment coefficient of -0.543 (P value 0.0001). As pulmonary score correlates well with PEFR, it can be used as an easy tool to measure the severity of bronchial asthma especially in peripheral centres where a peak flow meter may not be available. This helps in early referral.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
2298 Views
19 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved